For the second time this week, the Netherlands will gain the attention of the pharmaceutical industry, but the latest developments may not please many drug makers.
One day after Amsterdam was chosen as the next home of the European Medicines Agency, the government is readying debate over its pharmaceutical policies, but the session may be hijacked by concerns over high prices and the overall influence of drug makers, according to reports.
Left-wing political parties reportedly want to ban companies from sponsoring patient groups, encourage the government to override patents so cheaper alternatives can be made, and seek more transparency in reimbursements talks with drug makers. Meanwhile, one pharmacist is so upset about the cost of a patented Vertex Pharmaceuticals cystic fibrosis drug that he reportedly plans to find ways to make a lower-cost version himself.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect